The Center for Biosimilars® recaps the top stories from the first half of 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
The first half of 2020 has been a whirlwind time for the pharmaceutical industry in general between product launches, the coronavirus disease (COVID-19) pandemic causing companies to shift focus, to the World Health Organization (WHO) taking action to increase biosimilar access. Only time will tell what the rest of 2020 will hold for biosimilars.
Here are the top 5 biosimilars stories from January through June of 2020.
Number 5: In late 2019, Gilead Sciences submitted a New Drug Application (NDA) to the FDA for filgotinib under the priority review process. Filgotinib is a Janus kinase (JAK) inhibitor aimed at moderate-to-severe rheumatoid arthritis (RA).
Number 4: Stymied in its attempts to move forward with construction of a $514 million biosimilars manufacturing facility in Wuhan, China, Celltrion is trying another business strategy that may tide it through the current global economic crisis: It has joined the hunt for an antiviral treatment for COVID-19.
Number 3: As part of pilot program designed to improve access to cheaper medications in oncology, a rituximab biosimilar from Celltrion has been approved for use by the World Health Organization (WHO).
Number 2: In early January, Pfizer launched its bevacizumab biosimilar on the US market, Zirabev and priced it at a 23% discount to the WAC of reference product Avastin.
Number 1: The FDA’s new focus on COVID-19 and the quarantines imposed on much of the developed world have pushed digital and remote marketing of pharmaceutical products into high gear, according to Jamie Peck, managing director of iON.
To read all of these articles and more, visit centerforbiosimilars.com.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.